Legal Representation
Attorney
Rosemary S. Tarlton
USPTO Deadlines
Application History
26 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 15, 2008 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Apr 15, 2008 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Aug 6, 2007 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 6, 2007 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Aug 6, 2007 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Jan 19, 2007 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 19, 2007 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Jan 19, 2007 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Jul 13, 2006 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 13, 2006 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jul 13, 2006 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jun 5, 2006 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 23, 2006 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 23, 2006 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Jan 23, 2006 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Aug 5, 2005 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 5, 2005 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Aug 5, 2005 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Feb 8, 2005 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Nov 16, 2004 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 27, 2004 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Sep 15, 2004 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Aug 30, 2004 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Aug 25, 2004 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 20, 2004 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 9, 2004 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceuticals, namely implantable drug delivery system comprised primarily of sustained release drugs for the treatment of central nervous system disorders, cancer and other serious and life-threatening diseases
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005